Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, Loren S. Michel et al.|Clinical Cancer Research|2020Cited by 368
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancerGiacomo Oliveira, Ravindra Uppaluri, Ann Marie Egloff et al.|Science Immunology|2023Cited by 118
Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).Ravindra Uppaluri, Douglas R. Adkins, Rebecca D. Chernock et al.|Journal of Clinical Oncology|2021Cited by 40
Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, Katie M. Campbell et al.|Clinical Cancer Research|2021Cited by 14
Single-cell analysis highlights the significance of malignant cell IFN/MHC-II for immunotherapy response in head and neck squamous cell carcinomaMichael Mints, Sidharth V. Puram, Reilly A. Sample et al.|Cell Reports Medicine|2026Cited by 1